<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39339986</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>23</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Pfizer-BioNTech (BNT162b2) Vaccine Effectiveness against Symptomatic Laboratory-Confirmed COVID-19 Infection among Outpatients in Sentinel Sites, Lebanon, July-December 2021.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">954</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12090954</ELocationID><Abstract><AbstractText>On 14 February 2021, Lebanon implemented nationwide vaccination, offering the Pfizer-BioNTech (BNT162b2) vaccine to adults over 50 years of age. We estimated the effectiveness of the Pfizer-BioNTech vaccine in preventing symptomatic laboratory-confirmed COVID-19. We conducted a test-negative case-control (TND) study among symptomatic adults aged 50 years and older who presented with influenza-like illness (ILI) or COVID-19-like illness (CLI) in surveillance sentinel sites between 1 July and 31 December 2021. Unvaccinated participants did not receive any vaccine dose before symptom onset. Vaccinated participants received at least one dose within 14 days before onset of symptoms. We estimated vaccine effectiveness against symptomatic laboratory-confirmed COVID-19, adjusted for demographic and behavioral factors, using multivariable logistic regression. Out of 457 participants with symptoms, 150 (33%) were positive and 307 (67%) were negative for SARS-CoV-2. Adjusted vaccine effectiveness was 22% (95% CI: -70-65%) for those partially vaccinated and 44% (95% CI: 6-67%) for those fully vaccinated. Vaccination with two doses of the Pfizer-BioNTech vaccine was effective in preventing COVID-19 symptomatic illness in the older population. Vaccine effectiveness was lower for those partially vaccinated. We recommend enhancing vaccine uptake with at least one dose among risk groups for COVID-19 and keeping general recommendations on contact and droplet precautions in the general population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chaito</LastName><ForeName>Lina</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-1444-1416</Identifier><AffiliationInfo><Affiliation>Epidemiological Surveillance Program, Ministry of Public Health, Beirut 0127, Lebanon.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mediterranean and Black Sea Programme in Intervention Epidemiology Training (MediPIET), European Centre for Disease Prevention and Control (ECDC), 171 83 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stefanoff</LastName><ForeName>Pawel</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-0087-0906</Identifier><AffiliationInfo><Affiliation>Mediterranean and Black Sea Programme in Intervention Epidemiology Training (MediPIET), European Centre for Disease Prevention and Control (ECDC), 171 83 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baruch</LastName><ForeName>Joaquin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0806-3183</Identifier><AffiliationInfo><Affiliation>European Programme for Intervention Epidemiology Training Program (EPIET), European Centre for Disease Prevention and Control (ECDC), 171 83 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farah</LastName><ForeName>Zeina</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-1961-2600</Identifier><AffiliationInfo><Affiliation>Epidemiological Surveillance Program, Ministry of Public Health, Beirut 0127, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albuaini</LastName><ForeName>Mona</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0891-2499</Identifier><AffiliationInfo><Affiliation>National Influenza Center (NIC), Rafic Hariri University Hospital (RHUH), Beirut 0127, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghosn</LastName><ForeName>Nada</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-3549-703X</Identifier><AffiliationInfo><Affiliation>Epidemiological Surveillance Program, Ministry of Public Health, Beirut 0127, Lebanon.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">effectiveness</Keyword><Keyword MajorTopicYN="N">symptomatic outcome</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest. The author is a fellow of the MediPIET programme, supported financially by the European Centre for Disease Prevention and Control. The views and opinions expressed herein do not state or reflect those of ECDC. ECDC is not responsible for the data and information collation and analysis and cannot be held liable for conclusions or opinions drawn.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39339986</ArticleId><ArticleId IdType="pmc">PMC11436158</ArticleId><ArticleId IdType="doi">10.3390/vaccines12090954</ArticleId><ArticleId IdType="pii">vaccines12090954</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ministry of Public Health  Lebanon National Deployment and Vaccination Plan for COVID-19 Vaccines.  [(accessed on 10 March 2022)];2021  Available online:  https://www.moph.gov.lb/userfiles/files/Prevention/COVID-19%20Vaccine/Lebanon%20NDVP-%20Feb%2016%202021.pdf.</Citation></Reference><Reference><Citation>Kudlay D., Svistunov A. COVID-19 Vaccines: An Overview of Different Platforms. Bioengineering. 2022;9:72. doi: 10.3390/bioengineering9020072.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/bioengineering9020072</ArticleId><ArticleId IdType="pmc">PMC8869214</ArticleId><ArticleId IdType="pubmed">35200425</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashte S., Gulbake A., El-Amin S.F., III, Gupta A. COVID-19 Vaccines: Rapid Development, Implications, Challenges, and Future Prospects. Hum. Cell. 2021;34:711–733. doi: 10.1007/s13577-021-00512-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13577-021-00512-4</ArticleId><ArticleId IdType="pmc">PMC7937046</ArticleId><ArticleId IdType="pubmed">33677814</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi E.M. COVID-19 Vaccines for Low- and Middle-Income Countries. Trans. R. Soc. Trop. Med. Hyg. 2021;115:447–456. doi: 10.1093/trstmh/trab045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/trstmh/trab045</ArticleId><ArticleId IdType="pmc">PMC7989148</ArticleId><ArticleId IdType="pubmed">33733663</ArticleId></ArticleIdList></Reference><Reference><Citation>Merhi G., Trotter A.J., de Oliveira Martins L., Koweyes J., Le-Viet T., Abou Naja H., Al Buaini M., Prosolek S.J., Alikhan N.F., Lott M., et al. Replacement of the Alpha Variant of SARS-CoV-2 by the Delta Variant in Lebanon between April and June 2021. Microb. Genom. 2022;8:838. doi: 10.1099/mgen.0.000838.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/mgen.0.000838</ArticleId><ArticleId IdType="pmc">PMC9455693</ArticleId><ArticleId IdType="pubmed">35876490</ArticleId></ArticleIdList></Reference><Reference><Citation>Pormohammad A., Zarei M., Ghorbani S., Mohammadi M., Aghayari Sheikh Neshin S., Khatami A., Turner D.L., Djalalinia S., Mousavi S.A., Mardani-Fard H.A., et al. Effectiveness of COVID-19 Vaccines against Delta (B.1.617.2) Variant: A Systematic Review and Meta-Analysis of Clinical Studies. Vaccines. 2022;10:23. doi: 10.3390/vaccines10010023.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10010023</ArticleId><ArticleId IdType="pmc">PMC8778641</ArticleId><ArticleId IdType="pubmed">35062684</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang S., Liu H., Wu J., Xiao W., Chen S., Qiu S., Duan G., Song H., Zhang R. Effectiveness of BNT162b2 and mRNA-1273 Vaccines against COVID-19 Infection: A Meta-Analysis of Test-Negative Design Studies. Vaccines. 2022;10:469. doi: 10.3390/vaccines10030469.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10030469</ArticleId><ArticleId IdType="pmc">PMC8954872</ArticleId><ArticleId IdType="pubmed">35335101</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobczak M., Pawliczak R. COVID-19 Vaccination Efficacy in Numbers Including SARS-CoV-2 Variants and Age Comparison: A Meta-Analysis of Randomized Clinical Trials. Ann. Clin. Microbiol. Antimicrob. 2022;21:32. doi: 10.1186/s12941-022-00525-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12941-022-00525-3</ArticleId><ArticleId IdType="pmc">PMC9250750</ArticleId><ArticleId IdType="pubmed">35786399</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel M.M., Jackson M.L., Ferdinands J. Postlicensure Evaluation of COVID-19 Vaccines. JAMA. 2020;324:1939–1940. doi: 10.1001/jama.2020.19328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.19328</ArticleId><ArticleId IdType="pubmed">33064144</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control  Protocol for a COVID-19 Vaccine Effectiveness Study Using Health DataRegistries. Stockholm. 2023.  [(accessed on 12 March 2022)].  Available online:  https://www.ecdc.europa.eu/en/publications-data/protocol-covid-19-vaccine-effectiveness-study-using-health-data-registries.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention  COVID-19 Vaccine Effectiveness.  [(accessed on 14 July 2023)];2023  Available online:  https://www.cdc.gov/covid/php/surveillance/vaccine-effectiveness-studies.html.</Citation></Reference><Reference><Citation>World Health Organization  WHO Surveillance Case Definitions for ILI and SARI. Geneva. 2021.  [(accessed on 10 March 2022)].  Available online:  https://www.who.int/teams/global-influenza-programme/surveillance-and-monitoring/case-definitions-for-ili-and-sari.</Citation></Reference><Reference><Citation>World Health Organization  WHO COVID-19 Case Definitions. Geneva. 2020.  [(accessed on 20 March 2021)].  Available online:  https://apps.who.int/iris/rest/bitstreams/1322790/retrieve.</Citation></Reference><Reference><Citation>World Health Organization  Evaluation of COVID-19 Vaccine Effectiveness. Interim Guidance. Mar, 2021.  [(accessed on 15 February 2022)].  Available online:  https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccine_effectiveness-VE_evaluations-2022.1.</Citation></Reference><Reference><Citation>Chung H., He S., Nasreen S., Sundaram M.E., Buchan S.A., Wilson S.E., Chen B., Calzavara A., Fell D.B., Austin P.C., et al. Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines against Symptomatic SARS-CoV-2 Infection and Severe COVID-19 Outcomes in Ontario, Canada: Test Negative Design Study. BMJ. 2021;374:1943–1955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8377789</ArticleId><ArticleId IdType="pubmed">34417165</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez B.J., Andrews N., Gower C., Robertson C., Stowe J., Tessier E., Simmons R., Cottrell S., Roberts R., O’Doherty M., et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca Vaccines on COVID-19 Related Symptoms, Hospital Admissions, and Mortality in Older Adults in England: Test Negative Case-Control Study. BMJ. 2021;373:1088–1099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8116636</ArticleId><ArticleId IdType="pubmed">33985964</ArticleId></ArticleIdList></Reference><Reference><Citation>Martínez-Baz I., Miqueleiz A., Casado I., Navascués A., Trobajo-Sanmartín C., Burgui C., Guevara M., Ezpeleta C., Castilla J., Working Group for the Study of COVID-19 in Navarra Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection and Hospitalisation, Navarre, Spain, January to April 2021. Euro Surveill. 2021;26:2100438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8161727</ArticleId><ArticleId IdType="pubmed">34047271</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Tang P., Hasan M.R., AlMukdad S., Yassine H.M., Benslimane F.M., Al Khatib H.A., Coyle P., Ayoub H.H., Al Kanaani Z., et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N. Engl. J. Med. 2021;385:e83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8522799</ArticleId><ArticleId IdType="pubmed">34614327</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabiani M., Puopolo M., Morciano C., Spuri M., Spila Alegiani S., Filia A., D’Ancona F. Effectiveness of mRNA Vaccines and Waning of Protection against SARS-CoV-2 Infection and Severe COVID-19 during Predominant Circulation of the Delta Variant in Italy: Retrospective Cohort Study. BMJ. 2022;376:e069052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8829820</ArticleId><ArticleId IdType="pubmed">35144968</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan S.T., Kwan A.T., Rodríguez-Barraquer I., Singer B.J., Park H.J., Lewnard J.A., Sears D., Lo N.C. Infectiousness of SARS-CoV-2 Breakthrough Infections and Reinfections during the Omicron Wave. Nat. Med. 2023;29:358–365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9974584</ArticleId><ArticleId IdType="pubmed">36593393</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde M.W., Olson S.M., Self W.H., Talbot H.K., Lindsell C.J., Steingrub J.S., Shapiro N.I., Ginde A.A., Douin D.J., Prekker M.E., et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines against COVID-19 among Hospitalized Adults Aged ≥65 Years—United States, January–March 2021. MMWR Morb. Mortal. Wkly. Rep. 2021;70:674–679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9368749</ArticleId><ArticleId IdType="pubmed">33956782</ArticleId></ArticleIdList></Reference><Reference><Citation>Farah Z., Haddad N., Abou El Naja H., Saleh M., Mrad P., Ghosn N. Effectiveness of the Pfizer-BioNTech Vaccine against COVID-19-Associated Hospitalizations among Lebanese Adults ≥75 Years Old-Lebanon, April–May 2021. Epidemiologia. 2023;4:212–222. doi: 10.3390/epidemiologia4020022.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/epidemiologia4020022</ArticleId><ArticleId IdType="pmc">PMC10297521</ArticleId><ArticleId IdType="pubmed">37367187</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>